• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

疑似β-内酰胺类过敏患者在完成全面变态反应学评估后对书面医嘱的依从性:希腊一家三级医院的研究

Patient Adherence to Written Instructions following Complete Allergological Evaluation for Suspected Beta-Lactam Allergy: A Tertiary Hospital Study in Greece.

作者信息

Makris Michael, Papapostolou Niki, Pasali Maria, Aggelidis Xenofon, Chliva Caterina, Katoulis Alexander C

机构信息

Allergy Unit "D. Kalogeromitros", 2nd Department of Dermatology and Venereology, Medical School, University General Hospital "Attikon", National and Kapodistrian University of Athens, 12462 Athens, Greece.

2nd Department of Dermatology and Venereology, Medical School, University General Hospital "Attikon", National and Kapodistrian University of Athens, 12462 Athens, Greece.

出版信息

J Pers Med. 2023 Dec 17;13(12):1719. doi: 10.3390/jpm13121719.

DOI:10.3390/jpm13121719
PMID:38138946
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10745116/
Abstract

BACKGROUND

Beta-lactam (BL) antibiotics are among the most prescribed groups of drugs worldwide and have been implicated in a variety of allergic reactions. There is a paucity of literature regarding patient adherence to prescribed instructions following comprehensive allergy assessments.

OBJECTIVE

The objective was to follow up the clinical course of BL allergy in patients who underwent thorough allergological investigation for suspected BL allergy at a tertiary hospital and ascertain patients' compliance with the provided written instructions.

MATERIALS

An observational study in patients referred for suspected BL allergy who underwent a comprehensive allergy workup (in vivo ± in vitro tests, DPT in culprit and/or alternative BL) and who subsequently received written instructions was conducted. Data on the nature of the reported drug hypersensitivity reaction, the culprit BL drug, the allergological workup, and the detailed instructions provided in a written drug allergy report were collected retrospectively. Patients' compliance with the instructions was recorded by a telephone survey using a pre-defined questionnaire.

RESULTS

Among the 212 patients meeting the inclusion criteria, 87 patients (72.4% women; mean age 50.1 years; age range 6-84 years) responded to the telephone survey and were included in this study. Surprisingly, 45 out of 87 (51.7%) patients did not adhere to the written instructions. The primary factor contributing to non-compliance was the fear of re-occurrence of a drug-induced allergic reaction (personal and/or triggered by their treating physician reluctance), accounting for 77.7% of cases. The analysis demonstrated that the initial reaction's severity and type, as well as the outcomes of skin testing, did not correlate with compliance to instructions ( > 0.05). Surprisingly enough, a drug provocation test (DPT), irrespectively of the result, emerged as a negative predictor for adherence, with only 40.6% of DPT patients complying compared to 77.8% of those who did not undergo DPT ( = 0.005; odds ratio = 0.195; 95% confidence interval: 0.058-0.655). Variables such as performing DPT with alternative or incriminated drugs or the result of the DPT (positive-negative) were not associated with patient compliance. Conversely, the type of instructions provided exhibited a noteworthy correlation with compliance. Patients who were explicitly instructed to entirely avoid all BL antibiotics demonstrated markedly higher adherence rates (83.3%) compared to those who were advised to have a partial or complete release of BLs (31.8% and 58.1%, respectively; < 0.05). Notably, among compliant patients who received either the original culprit drug or the alternative (32 out of 87, 36.7%), no allergic reactions were reported. In contrast, among the 12 patients with written avoidance of all BLs, subsequent BL intake led to immediate reactions (Grade I and IV) in 2 patients (16.6%).

CONCLUSIONS

A notable disparity in patient adherence to written instructions prohibiting or releasing beta-lactams was demonstrated. Less than half of the patients ultimately complied with the provided instructions, underscoring the need for tailored patients' education and strategies to improve adherence in the management of suspected BL allergy.

摘要

背景

β-内酰胺(BL)类抗生素是全球处方量最大的药物类别之一,与多种过敏反应有关。关于患者在接受全面过敏评估后对医嘱的依从性,相关文献较少。

目的

对在一家三级医院因疑似BL过敏而接受全面过敏学检查的患者进行BL过敏临床病程随访,并确定患者对所提供书面医嘱的依从性。

材料

对因疑似BL过敏前来就诊并接受全面过敏检查(体内和/或体外试验、对可疑和/或替代BL进行药物激发试验)且随后收到书面医嘱的患者进行了一项观察性研究。回顾性收集了关于所报告药物过敏反应的性质、可疑BL药物、过敏学检查以及书面药物过敏报告中提供的详细医嘱的数据。通过使用预定义问卷的电话调查记录患者对医嘱的依从性。

结果

在符合纳入标准的212例患者中,87例患者(72.4%为女性;平均年龄50.1岁;年龄范围6 - 84岁)回复了电话调查并纳入本研究。令人惊讶的是,87例患者中有45例(51.7%)未遵守书面医嘱。导致不依从的主要因素是担心药物引起的过敏反应再次发生(个人原因和/或因治疗医生的不情愿而引发),占病例的77.7%。分析表明,初始反应的严重程度和类型以及皮肤试验结果与医嘱依从性无关(P>0.05)。令人惊讶的是,无论结果如何,药物激发试验(DPT)都成为依从性的负预测因素,进行DPT的患者中只有40.6%遵守医嘱,而未进行DPT的患者中这一比例为77.8%(P = 0.005;比值比 = 0.195;95%置信区间:0.058 - 0.655)。使用替代药物或可疑药物进行DPT以及DPT结果(阳性 - 阴性)等变量与患者依从性无关。相反,所提供医嘱的类型与依从性呈现出显著相关性。被明确指示完全避免所有BL抗生素的患者的依从率(83.3%)明显高于被建议部分或完全解禁BL的患者(分别为31.8%和58.1%;P<0.05)。值得注意的是,在接受了原始可疑药物或替代药物的依从性患者中(87例中的32例,36.7%),未报告过敏反应。相比之下,在12例书面要求避免所有BL的患者中,随后摄入BL导致2例患者(16.6%)立即出现反应(I级和IV级)。

结论

在患者对禁止或解禁β-内酰胺类药物的书面医嘱的依从性方面存在显著差异。不到一半的患者最终遵守了所提供的医嘱,这突出表明需要进行有针对性的患者教育并制定策略以提高在疑似BL过敏管理中的依从性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f16/10745116/a36a3d093f98/jpm-13-01719-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f16/10745116/fd34f414fb33/jpm-13-01719-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f16/10745116/919517833bee/jpm-13-01719-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f16/10745116/a6ebde7835b8/jpm-13-01719-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f16/10745116/a36a3d093f98/jpm-13-01719-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f16/10745116/fd34f414fb33/jpm-13-01719-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f16/10745116/919517833bee/jpm-13-01719-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f16/10745116/a6ebde7835b8/jpm-13-01719-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f16/10745116/a36a3d093f98/jpm-13-01719-g004.jpg

相似文献

1
Patient Adherence to Written Instructions following Complete Allergological Evaluation for Suspected Beta-Lactam Allergy: A Tertiary Hospital Study in Greece.疑似β-内酰胺类过敏患者在完成全面变态反应学评估后对书面医嘱的依从性:希腊一家三级医院的研究
J Pers Med. 2023 Dec 17;13(12):1719. doi: 10.3390/jpm13121719.
2
Safety of direct oral provocation test to delabel reported mild beta-lactam allergy in infants.直接口服激发试验以重新标记婴儿报告的轻度β-内酰胺过敏的安全性。
Allergol Immunopathol (Madr). 2024 Mar 1;52(2):10-15. doi: 10.15586/aei.v52i2.887. eCollection 2024.
3
Outcome of drug provocation testing in children with suspected beta-lactam hypersensitivity.疑似β-内酰胺过敏儿童的药物激发试验结果
Asia Pac Allergy. 2021 Jan 14;11(1):e3. doi: 10.5415/apallergy.2021.11.e3. eCollection 2021 Jan.
4
Risk Factors of Challenge-Proven Beta-Lactam Allergy in Children with Immediate and Non-Immediate Mild Cutaneous Reactions.有即时和非即时轻度皮肤反应的儿童经挑战证实的β-内酰胺类过敏的危险因素。
Int Arch Allergy Immunol. 2023;184(6):539-549. doi: 10.1159/000529084. Epub 2023 Mar 1.
5
Delabelling beta-lactam allergy.去除β-内酰胺类过敏标记。
Front Pharmacol. 2024 Jun 27;15:1423719. doi: 10.3389/fphar.2024.1423719. eCollection 2024.
6
Challenging dogmas: Intravenous versus oral beta-lactam antibiotic provocation tests.挑战传统观念:静脉注射与口服β-内酰胺类抗生素激发试验
World Allergy Organ J. 2024 May 24;17(6):100914. doi: 10.1016/j.waojou.2024.100914. eCollection 2024 Jun.
7
Approach for delabeling beta-lactam allergy in children.儿童β-内酰胺类药物过敏标签去除方法。
Front Allergy. 2023 Nov 15;4:1298335. doi: 10.3389/falgy.2023.1298335. eCollection 2023.
8
Skin tests are important in children with β-lactam hypersensitivity, but may be reduced in number.皮肤试验在β-内酰胺类药物过敏的儿童中很重要,但可能会减少。
Pediatr Allergy Immunol. 2019 Jun;30(4):462-468. doi: 10.1111/pai.13041. Epub 2019 Mar 19.
9
Natural History of Benign Nonimmediate Allergy to Beta-Lactams in Children: A Prospective Study in Retreated Patients After a Positive and a Negative Provocation Test.儿童良性非即刻型β-内酰胺类过敏的自然史:阳性和阴性激发试验后撤退患者的前瞻性研究。
J Allergy Clin Immunol Pract. 2018 Jul-Aug;6(4):1321-1326. doi: 10.1016/j.jaip.2017.10.008. Epub 2017 Nov 23.
10
Adding a second skin prick test reading and modifying the cut-off for beta-lactam-specific IgE enhances the sensitivity in the routine diagnostic workup for immediate beta-lactam hypersensitivity.增加第二次皮肤点刺试验读数并修改β-内酰胺特异性IgE的临界值可提高速发型β-内酰胺超敏反应常规诊断检查的敏感性。
Contact Dermatitis. 2020 Nov;83(5):361-371. doi: 10.1111/cod.13622. Epub 2020 Jul 27.

引用本文的文献

1
Can Labs Help With Vaccination? In Vitro Tests in Diagnosis of Allergy to COVID-19 Vaccines-A Systematic Review.实验室能否助力疫苗接种?新冠疫苗过敏诊断中的体外检测——一项系统评价。
Immun Inflamm Dis. 2025 May;13(5):e70206. doi: 10.1002/iid3.70206.

本文引用的文献

1
Penicillin de-labelling in vancouver, British Columbia, Canada: comparison of approaches, outcomes and future directions.加拿大不列颠哥伦比亚省温哥华市的青霉素去标签化:方法、结果及未来方向的比较
Allergy Asthma Clin Immunol. 2023 Apr 18;19(1):30. doi: 10.1186/s13223-023-00777-4.
2
Drug allergy: A 2022 practice parameter update.药物过敏:2022年实践参数更新
J Allergy Clin Immunol. 2022 Dec;150(6):1333-1393. doi: 10.1016/j.jaci.2022.08.028. Epub 2022 Sep 17.
3
Drug Allergy Labels Lost in Translation: From Patient to Charts and Backwards.
药物过敏标签翻译有误:从患者到病历再到患者。
J Allergy Clin Immunol Pract. 2021 Aug;9(8):3015-3020. doi: 10.1016/j.jaip.2021.02.005. Epub 2021 Feb 16.
4
Safety, Efficacy, and Effectiveness of Delabeling in Patients with Multiple Drug Allergy Labels.多药过敏标签患者去标签化的安全性、有效性和效果。
J Allergy Clin Immunol Pract. 2021 Feb;9(2):922-928. doi: 10.1016/j.jaip.2020.09.010. Epub 2020 Sep 20.
5
DALES, Drug Allergy Labels in Elective Surgical patients: a prospective multicentre cross-sectional study of incidence, risks, and attitudes in penicillin de-labelling strategies.《选择性手术患者中的药物过敏标签:去青霉素标签策略中的发生率、风险和态度的前瞻性多中心横断面研究》。
Br J Anaesth. 2020 Dec;125(6):962-969. doi: 10.1016/j.bja.2020.07.048. Epub 2020 Aug 25.
6
Drug allergy labeling and delabeling in the coronavirus disease 2019 era: What is important and what do we need to know.2019年冠状病毒病时代的药物过敏标签标注与去除标注:重要的是什么以及我们需要了解什么。
Ann Allergy Asthma Immunol. 2020 Jun;124(6):523-525. doi: 10.1016/j.anai.2020.04.012.
7
Drug allergy delabeling in the clinical setting: An all-hands-on-deck opportunity.临床环境中的药物过敏去标签:全员参与的契机。
Ann Allergy Asthma Immunol. 2020 Jun;124(6):542-543. doi: 10.1016/j.anai.2020.02.017. Epub 2020 Mar 6.
8
Addressing the epidemic of antibiotic "allergy" over-diagnosis.解决抗生素“过敏”过度诊断的流行问题。
Ann Allergy Asthma Immunol. 2020 Jun;124(6):550-557. doi: 10.1016/j.anai.2019.12.016. Epub 2019 Dec 24.
9
Penicillin Allergy.青霉素过敏
N Engl J Med. 2019 Dec 12;381(24):2338-2351. doi: 10.1056/NEJMra1807761.
10
Towards a more precise diagnosis of hypersensitivity to beta-lactams - an EAACI position paper.迈向更精准的β-内酰胺类药物超敏反应诊断——欧洲变态反应和临床免疫学会立场文件
Allergy. 2020 Jun;75(6):1300-1315. doi: 10.1111/all.14122.